🇺🇸 FDA
Patent

US 7884111

2,4-pyrimidinediamine compounds and uses as anti-proliferative agents

granted A61KA61K31/4353A61K31/505

Quick answer

US patent 7884111 (2,4-pyrimidinediamine compounds and uses as anti-proliferative agents) held by Rigel Pharmaceuticals, Inc. expires Mon Feb 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Feb 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/4353, A61K31/505, A61K31/506, A61P